Name: Steve La Neve
New title: CEO, Accuray
Previous title: President, trauma and joint reconstruction, Globus Medical
Accuray named medtech industry veteran Steve La Neve CEO as part of a transformation plan at the radiation therapy systems maker.
The appointment, effective immediately, comes as the company accelerates initiatives designed to expand margins, improve competitiveness and drive sustainable, profitable growth, Accuray said this week. Most of the organizational, strategic and operational actions will be implemented during the current fiscal year ending in June.
La Neve succeeds Suzanne Winter, who will retire as president and CEO after six years with the company. Winter will remain in an advisory role through November.
The new CEO, who has more than 40 years of medtech industry experience, previously was president of Globus Medical’s trauma and joint reconstruction business unit. Past roles include CEO of Bone Biologics, global president of Becton Dickinson’s preanalytical systems and global sector president for Medtronic's spine and biologics division.
Accuray also named Steven Mayer as transformation board sponsor to work with La Neve and the management team. Mayer, who joined Accuray’s board in June, is the former executive chairman of Grifols, where he led a turnaround, and previously spent nearly two decades as senior managing director at Cerberus Capital Management.
Along with the leadership and strategy announcement, Accuray released preliminary fiscal first-quarter 2026 results, reporting an adjusted loss before interest, tax, depreciation and amortization of about $4 million, on revenue of $92.5 million to $94 million.
For fiscal year 2025, Accuray reported in August that it lost $1.6 million, compared to a net loss of $15.5 million in the prior fiscal year. Revenue increased 3% year over year to $458.5 million.
In the past year, the company has struggled with challenges including slower order demand in the U.S. as hospitals delayed replacing capital equipment.
